Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ascentage Pharma Group International (6855.HK)
Suzhou, CN
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation. This compound is intended for patients suffering from chronic phase chronic myeloid leukemia that has become resistant to tyrosine kinase inhibitors. Beyond HQP1351, the company boasts a robust pipeline. This includes APG-2575 (Pelcitoclax), an orally administered, selective Bcl-2 inhibitor undergoing Phase Ib/II clinical studies for hematologic and solid tumors; APG-115 (Alrizomadlin), an oral small molecule designed to inhibit the MDM2-p53 protein-protein interaction for various solid and hematological malignancies; and APG-1387 (Nevadotinib), a small molecule inhibitor of apoptosis proteins targeting advanced solid tumors and chronic HBV infections. Further advancing its portfolio, Ascentage is developing APG-1252 (Atoloclab), a small molecule drug aimed at restoring apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins for conditions such as small cell lung cancer (SCLC), lymphoma, and other solid tumors. The pipeline also features APG-2449 (Glecirasib) for non-small-cell lung carcinoma (NSCLC); APG-5918, an orally available and selective EED inhibitor with best-in-class potential in its preclinical phase; APG-265, currently in IND-enabling stages for hematological and solid tumors; and UBX1967/1325, a Phase II candidate targeting the Bcl family for diabetic macular edema (DME). The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical companies, as well as academic institutions. Key partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Established in 2009, Ascentage Pharma is headquartered in Suzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.70% | -5.49% | -12.14% | -16.33% | -38.83% | -24.90% | -21.75% | +96.79% | -17.74% | +4.36% | +4.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-43.0% Q4'25: +322.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-153.7% Q4'25: +3.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-237.3% Q4'25: -235.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-211.1% Q4'25: -191.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-139.9% Q4'25: -304.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+17.9% Q4'25: +27.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.81× Q4'25: -0.83× (vs Q4'23)
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 4 EPS Ana. |
Dec 2027 10 Rev. Ana. 4 EPS Ana. |
Dec 2028 8 Rev. Ana. 3 EPS Ana. |
Dec 2029 7 Rev. Ana. 1 EPS Ana. |
Dec 2030 7 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.51M
est: 6.90M (+110.4%)
|
12.45M
est: 6.98M (+78.3%)
|
27.91M
est: 38.06M (-26.7%)
|
209.71M
est: 264.55M (-20.7%)
|
221.98M
est: 840.00M (-73.6%)
|
980.65M
est: 1.12B (-12.2%)
|
559.26M
est: 525.04M (+6.5%)
|
954.70M
670.65M – 1.33B
+81.8% YoY
|
1.53B
859.12M – 3.13B
+60.4% YoY
|
2.59B
1.59B – 4.67B
+68.8% YoY
|
3.11B
1.91B – 5.61B
+20.2% YoY
|
5.50B
3.37B – 9.92B
+76.9% YoY
|
| EBITDA |
-1.45B
est: -5.94M (-24,342.3%)
|
-641.77M
est: -2.19B (+70.7%)
|
-915.99M
est: -18.58B (+95.1%)
|
-835.99M
est: -88.19B (+99.1%)
|
-743.61M
est: -723.33M (-2.8%)
|
-299.63M
est: -12.44T (+100.0%)
|
-1.10B
est: -452.12M (-142.5%)
|
-822.10M
-1.15B – -577.50M
-81.8% YoY
|
-1.32B
-2.70B – -739.79M
-60.4% YoY
|
-2.23B
-4.02B – -1.37B
-68.8% YoY
|
-2.68B
-4.83B – -1.64B
-20.2% YoY
|
-4.73B
-8.55B – -2.90B
-76.9% YoY
|
| EBIT |
-1.48B
est: -6.05M (-24,329.3%)
|
-669.19M
est: -2.22B (+69.9%)
|
-933.17M
est: -18.81B (+95.0%)
|
-883.41M
est: -89.27B (+99.0%)
|
-836.81M
est: -736.89M (-13.6%)
|
-378.80M
est: -12.59T (+100.0%)
|
-1.18B
est: -460.60M (-156.4%)
|
-837.52M
-1.17B – -588.33M
-81.8% YoY
|
-1.34B
-2.75B – -753.67M
-60.4% YoY
|
-2.27B
-4.10B – -1.39B
-68.8% YoY
|
-2.73B
-4.92B – -1.67B
-20.2% YoY
|
-4.82B
-8.71B – -2.96B
-76.9% YoY
|
| Net Income |
-1.48B
est: -1.54B (+4.0%)
|
-677.61M
est: -2.22B (+69.5%)
|
-782.42M
est: -18.84B (+95.8%)
|
-882.92M
est: -878.54M (-0.5%)
|
-925.64M
est: -335.14M (-176.2%)
|
-405.43M
est: -1.06B (+61.7%)
|
-1.21B
est: -760.31M (-59.2%)
|
-776.48M
-927.15M – -365.88M
-2.1% YoY
|
-604.56M
-1.64B – 679.17M
+22.1% YoY
|
19.39M
-481.37M – 46.12M
+103.2% YoY
|
-509.96M
-1.04B – -253.51M
-2,730.4% YoY
|
447.56M
222.49M – 916.35M
+187.8% YoY
|
| SGA |
161.64M
est: 28.93M (+458.8%)
|
130.34M
est: 29.29M (+345.0%)
|
191.26M
est: 159.63M (+19.8%)
|
328.02M
est: 1.11B (-70.4%)
|
376.46M
est: 1.92B (-80.4%)
|
383.12M
est: 2.55B (-85.0%)
|
523.40M
est: 1.20B (-56.4%)
|
2.18B
1.53B – 3.05B
+81.8% YoY
|
3.50B
1.97B – 7.17B
+60.4% YoY
|
5.92B
3.63B – 10.68B
+68.8% YoY
|
7.11B
4.36B – 12.84B
+20.2% YoY
|
12.57B
7.71B – 22.71B
+76.9% YoY
|
| EPS |
-12.69
est: -5.10 (-148.6%)
|
-3.14
est: -3.28 (+4.4%)
|
-3.07
est: -2.59 (-18.4%)
|
-3.35
est: -3.18 (-5.3%)
|
-3.28
est: -1.15 (-184.7%)
|
-1.34
est: -0.47 (-186.7%)
|
-3.40
est: -2.22 (-52.9%)
|
-1.86
-2.60 – -1.03
+16.5% YoY
|
-0.90
-4.61 – 1.91
+51.5% YoY
|
-0.46
-1.35 – 0.13
+48.8% YoY
|
-1.43
-2.93 – -0.71
-210.5% YoY
|
1.26
0.62 – 2.57
+187.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.86% | 556.7K | 0.59% |
| 2 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.16% | 607.8K | 0.47% |
| 3 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.15% | 572.6K | 0.50% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.12% | 85.8K | 0.74% |
| 5 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.09% | 467.4K | 0.32% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.08% | 504.3K | 0.55% |
| 7 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.08% | 302.1K | 0.72% |
| 8 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.08% | 262.9K | 0.74% |
| 9 | State Street SPDR S&P China ETF GXC | 0.04% | 165.4K | 0.59% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 4.74M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dajun Yang | Co-Founder, Chairman & Chief Executive Officer | 48M | — |
| Shaomeng Wang | Co-Founder, Chief Scientific Advisor & Non-Executive Director | 2M | — |
| Hoi Yan Leung | Company Secretary | — | female |
| Jin Cao | Head of Finance | — | male |
| Manish Tandon | SVP of Business Development | — | — |
| Ming Guo | Co-Founder | — | — |
| Thomas Joseph Knapp | Senior Vice President & General Counsel | — | male |
| Veet Misra | Chief Financial Officer | — | — |
| Yifan Zhai | Chief Medical Officer | — | — |
| Yuly Chen | Senior Director of Investor Relations | — | — |
| Chongdong Fu | Senior Vice President & Head of CMC | — | — |
| Zhichao Si | Head of Commercial | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6855.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
